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A B S T R A C T
The chemical distribution and mechanical effects of drug compounds in loaded electrospun scaffolds, a
potential material for hernia repair mesh, were characterised and the efﬁcacy of the material was
evaluated. Polycaprolactone electrospun ﬁbres were loaded with either the antibacterial agent, irgasan,
or the broad-spectrum antibiotic, levoﬂoxacin. The samples were subsequently characterised by
rheological studies, scanning electron microscopy (SEM), atomic force microscopy (AFM), contact angle
goniometry (CAG), in vitro drug release studies, antibacterial studies and time-of-ﬂight secondary ion
mass spectrometry (ToF-SIMS). Increased linear viscoelastic regions observed in the rheometry studies
suggest that both irgasan and levoﬂoxacin alter the internal structure of the native polymeric matrix. In
vitro drug release studies from the loaded polymeric matrix showed signiﬁcant differences in release
rates for the two drug compounds under investigation. Irgasan showed sustained release, most likely
driven by molecular diffusion through the scaffold. Conversely, levoﬂoxacin exhibited a burst release
proﬁle indicative of phase separation at the edge of the ﬁbres. Two scaffold types successfully inhibited
bacterial growth when tested with strains of E. coli and S. aureus. Electrospinning drug-loaded polyester
ﬁbres is an alternative, feasible and effective method for fabricating non-woven ﬁbrous meshes for
controlled release in hernia repair.
© 2016 Elsevier B.V. All rights reserved.
1. Introduction
Hernia repair, one of the most common general surgeries
performed, is complicated by bacterial infections and implant
rejection (Earle, 2010). Commercially available mesh devices
currently employed in hernia repairs contain brained or knitted
ﬁbres. The mechanical properties of the mesh and the biocom-
patibility of the material are critical to the healing process. Tissue
incorporation, a key factor in the success of the graft device is
dependent on the material type, density, compliance and electrical
properties of the mesh (Procter et al., 2009). Graft failure motivates
research into new fabrication methods for incorporating bio-
materials and drug encapsulation in novel mesh matrices, such as
hot-melt extrusion (Li et al., 2013), electrospinning (Toncheva
et al., 2011), 3D printing (Holländer et al., 2016) and high-speed
rotary spinning (Sebe et al., 2013).
Electrospinning is the most popular and preferred technique for
nanoﬁber fabrication due to its simplicity, cost-effectiveness,
ﬂexibility, and ability to spin a broad range of polymers (Zamani
et al., 2013). The method allows for the simple and direct
functionalization of ﬁbres with drug compounds and is compatible
with solvents such as chloroform and dimethyl sulfoxide. In
addition, the process of electrospinning with the use of solvents
such as chloroform, dimethyl sulfoxide etc., allows functionalisa-
tion of the scaffolds through the inclusion of drugs in the polymer-
solvent solution without the need for a complicated preparation
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process (He et al., 2015). Electrospinning has previously been
applied to the fabrication of triclosan/cyclodextrin inclusion
complexes (Celebioglu et al., 2014), the construction of scaffolds
with perlecan domain IV peptides (Hartman et al., 2011),
manufacture of biocatalytic protein membranes (Kabay et al.,
2016), and encapsulation of levoﬂoxacin in mesoporous silica
nanoparticles (Jalvandi et al., 2015). Given the broad applications of
electrospinning, there has been previous research speciﬁcally
focused on the development of electrospun polymeric materials
for hernia repair mesh devices. Electrospinning produces scaffolds
containing micro-ﬁbres and this is an advantageous feature not
observed in braided mesh commercial devices  these microﬁbers
also introduce mechanical anisotropy and provide topographic
features to guide cell alignment (Goldstein and Thayer, 2016).
However, electrospun ﬁbres typically incorporate the use of
organic solvents and for applications such as hernia repair or
tissue engineering, the toxicity of organic solvents used could be
highly critical – avoiding organic solvents is of outmost importance
for applications in medicine and pharmacy (Agarwal and Greiner,
2011; Bubel et al., 2014).
The purpose of this study is to examine the physicochemical
properties, bacteria response, and drug loading of electrospun
scaffolds. The polymer chosen for this study is polycaprolactone
(PCL); a biodegradable polyester commonly used in biomedical
applications for controlled release and targeted drug delivery
(Bhavsar and Amiji, 2008). PCL, a biodegradable aliphatic polyester
(Azimi et al., 2016), is an obvious candidate for drug delivery
systems due to its high biocompatibility and ease of degradation in
the human body (Bikiaris et al., 2007). Drug loading of structures
that mechanically resemble interfacial tissue and which allows
short or long-term release of suitable bioactives may be utilisable
in hernia-repair meshes. PCL was chosen in this research as it has a
high permeability to a variety of drug molecules (e.g. gentamycin,
chitosan) and low toxicity (Murthy, 1997). The matrix was loaded
and electrospun with two drugs, irgasan (an antibacterial agent
used commonly in soaps, detergents and surgical cleaning agents)
or levoﬂoxacin (a broad-spectrum antibiotic used commonly to
treat gastrointestinal infections). The mechanical characteristics,
morphology, surface hydrophobicity, drug efﬁcacy and chemical
distribution were characterised with an array of analytical
techniques. The results from this study should help to build
platform to aid future work with various fabrication methods, such
as extrusion and shaping using 3D printing.
2. Materials & methods
2.1. Materials
Polycaprolactone (PCL) with a mean molecular weight of 80 kD,
Irgasan (variation of Triclosan, >97%), Levoﬂoxacin (>98%), and all
the solvents used for the electrospinning were obtained from
Sigma Aldrich. The solvents consisting of chloroform (anhydrous,
containing amylenes as stabilizers, >99%) and N,N-dimethylfor-
mamide (DMF, anhydrous 99.8%).
2.2. Preparation of PCL solutions
Different solutions with a polymer concentration of 12% (w/w)
were prepared to be used within the electrospinning method – this
particular concentration was used due to its possessed suture
retention and tensile strengths appropriate for hernia repair, as
speciﬁed for similar electrospun scaffolds described by Ebersole
et al. (2012). Various PCL formulations were constructed of a total
weight of 25 g per solution, which allowed for PCL (12% w/w) and a
9:1 (w/w) ratio of chloroform (CLF) to N,N-dimethylformamide
(DMF). For the unloaded polymer solution, 3 g of PCL was dissolved
in 22 g of CLF:DMF (9:1) which was initially mixed through 30 min
in a centrifuge, a further 30 min in a sonicator (Elma S30
Elmasonic) and a ﬁnal 1 h with a magnetic stirrer. This process
was vital to ensure that the solution was fully homogeneous. The
solution was left overnight, and a further 30 min of sonication
applied the following morning in order to conﬁrm the homogene-
ity of the solution. For the irgasan-loaded solutions, the same
method was applied, except the solution contained 1% (w/w)
irgasan. The concentration of the levoﬂoxacin-loaded solutions
was 0.5% (w/w), providing sufﬁcient sensitivity in the release cell
for accurate UV analysis. All the preparations turned to clear
solutions. These observations were interpreted to determine that
the solutions had successfully homogenised. The solutions were
then subsequently used in the electrospinning process and for
rheological analysis.
2.3. Electrospinning of PCL solutions
The PCL test specimens were fabricated for each polymeric
solution, using a custom in-house electrospinning apparatus,
which consisted of a syringe pump (Harvard Apparatus PHD 2000
infusion, US) and two 30 kV high-voltage power supplies (Alpha III
series, Brandenburg, UK). The polymer solution was loaded into
glass syringe and fed through tubing with a metal needle tip
attached at the end. The needle was clamped into place, to allow a
high-voltage supply to run through it, which allowed an electric
ﬁeld to be created between the needle and the target plate. The
syringe was clamped to a pump, which determined the speciﬁc
injection ﬂow rate of the polymeric solutions. For each of the three
solutions (e.g. unloaded, irgasan-loaded, and levoﬂoxacin-loaded),
3 varying ﬂow rates of 0.5, 1 and 1.5 ml h1 were applied across
varying voltages of 2 kV–5 kV (needle) and 10 kV–18 kV (target
plate). The variation in ﬂow rate and applied voltages was to
correct any problems that occurred during fabrication, i.e. ‘spitting’
of solution at the target plate, or any potential beading (which was
examined through SEM). The fabrication of this solution was
electrospun onto the target that was covered with aluminium foil,
in order for the ﬁnal material to be removed and used for further
characterisation. The ﬁnal yield of electrospun PCL resulted in thin,
ﬂexible sheets of material.
2.4. Rheological studies
A Thermo Scientiﬁc HAAKE MARS II rheometer with a P35 TiL
cone and plate was used to measure the rheological and
mechanical behaviour of the different unloaded and loaded
polymeric solutions. The objective of this experiment was to
examine the viscoelastic properties of the PCL solution, speciﬁcally
to determine whether the irgasan or levoﬂoxacin is having an
effect on the mechanical properties of the polymer. The method
used was taken and modiﬁed from the rheological study
undertaken by Bubel et al. (2014). In brieﬂy, an oscillating
amplitude sweep between 0.1 Pa–1000 Pa at a frequency of 1 Hz
was used to determine the linear viscoelastic region (LVER) of the
samples. Once the LVER is determined from the amplitude sweep, a
downwards oscillating frequency sweep from 10 Hz–0.1 Hz with a
shear stress (Pa) within the LVER was then used in order to help
understand the nature of the solutions concerning strength and
stability. The experiments were repeated 4 times per solution, and
for each experiment, each data point (20 data points per method)
was optimised to repeat each measurement 5 times.
2.5. Scanning electron microscopy (SEM)
The morphology and diameter of individual ﬁbres spun from
PCL solution were determined from scanning electron micrographs
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of each sample (TM-1000, Hitachi, UK, Ltd.). The samples were
mounted on an aluminium plate with conductive tape. Images of
ﬁbres were taken at various locations of each electrospun PCL
scaffold in order to determine the overall uniformity of ﬁbres. Prior
to imaging, the samples were sputter coated with gold for 30 s
using a Leica EM ACE200 vacuum coater, the process being
repeated four times in order to increase the conductivity of the
samples.
2.6. Atomic force microscopy (AFM)
Further morphological analysis was undertaken through atomic
force microscopy. A Multimode 8 microscope (Bruker, USA), with
Scanasyst-Air probes (Bruker, USA) was used in Peak Force
Quantitative Nano Mechanics (QNM) mode, as described by
Lamprou et al. (2013). The imaging of the ﬁbres was performed
under ambient conditions, with a silicon cantilever probe. The tip
radius of the probe and the spring constant were calculated to be in
the regions of 0.964 nm (18 tip half angle) and 0.4935 N/m,
respectively. The scan sizes ranged from 200 nm to 25 mm, at a scan
rate of 0.977 Hz with 256-sample resolution. The Roughness
Average (Ra) values were determined by entering surface scanning
data, and digital levelling algorithm values were determined using
Nanoscope Analysis software V1.40 (Bruker USA). AFM images
were collected from two different samples and at random spot
surface sampling.
2.7. Contact angle goniometry (CAG)
To monitor changes in wettability of the scaffolds, sessile drop
contact angle for distilled water was measured by contact angle
goniometry, using a contact angle goniometer (Kruss G30,
Germany) as described by Lamprou et al. (2010).
2.8. In vitro drug release studies
The drug releases of the irgasan/levoﬂoxacin loaded PCL
scaffolds were measured in order to determine the release proﬁle
of the drugs. Samples of PCL-IRG were immersed in phosphate
buffered saline (PBS) containing 0.5% sodium dodecyl sulphate
(SDS) at 37 C, and samples of PCL-LEVO were immersed in PBS
only at 37 C. This release study was based on the method cited by
Duan et al. (2013). The solutions were agitated using a shaker at a
rate of 80 rev/min. The UV absorbance of both drugs was
measured: irgasan at 280 nm (Piccoli et al., 2002), and levoﬂoxacin
at 292 nm (Maleque et al., 2012) respectively. Measurements were
taken at intervals at 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 24 h and every
day after the 24 h mark for up to 7 days. At each point, 4 ml of
solution was taken from the vial and replaced with fresh in order to
satisfy the perfect-sink conditions and keeping the volume of the
solution constant.
2.9. Antibacterial studies
The antibacterial efﬁcacy of the drug loaded electrospun
scaffolds were tested against Escherichia coli (E. coli) 8739 and
Staphylococcus aureus (S. aureus) 29213. S. aureus is Gram positive,
E. coli is Gram negative and both bacteria are common causes of
nosocomial infections. Both irgasan and levoﬂoxacin should have
antibacterial effects. For this study, an agar diffusion method was
used. Luria-Bertani (LB) agar was prepared from a formulation of
5 g tryptone, 2.5 g yeast extract, 5 g NaCl in 475 ml of deionized
water. The LB agar was autoclaved and poured into 20 ml plates.
The E. coli and S. aureus were grown overnight in 5 ml of LB Broth,
with both bacteria inoculated from a single colony. 150 ml of the
E. coli and S. aureus cultures were spread onto six different plates of
LB agar. Three plates consisted of spread E. coli, including a scaffold
free plate, which acted as a control – the other 2 plates, were
divided into 4 sections, with 1 section containing an unloaded PCL
scaffold, and the other 3 containing PCL-irgasan and
PCL-levoﬂoxacin scaffolds. This procedure was repeated for three
plates of spread S. aureus. The plates were incubated for 24 h, and
subsequently examined. Diameters of the zones of growth
inhibition were measured, and these data compared across the
drugs and bacterial strains. This method was based on the method
described by Davachi et al. (2016).
2.10. Time of ﬂight secondary ion mass spectrometry (ToF-SIMS)
ToF-SIMS data was acquired using a ToF-SIMS V mass
spectrometer (ION-TOF GmbH, Münster, Germany) based at the
Wolfson Foundation Pharmaceutical Surfaces Laboratory at the
University of Strathclyde. The instrument is equipped with a
bismuth liquid metal ion gun (LMIG), an argon gas cluster ion beam
(GCIB) and a gridless reﬂectron time-of-ﬂight mass analyzer.
Three different acquisition modes, detailed below, were used to
analyse the ﬁbres: high mass resolution spectroscopy, depth
proﬁling, high lateral resolution imaging. Owing to the insulative
nature of the materials, a low-energy electron beam (21 V) was
used to compensate for charging.
2.10.1. High mass resolution spectroscopy
For an optimal mass resolution, the primary ion beam (Bi3
+
primary ions) was pulsed at 10 kHz frequency with a pulse width of
17.0 ns. The primary ion gun energy was set at 30 kV and the pulsed
target current was approximately 0.63 pA. Data was collected both
in the positive and in the negative secondary ion polarities, in three
replicates; each acquisition was made from different areas of the
samples used in this study. The analysed area and the acquisition
time, for each repetition, were respectively 100 mm  100 mm and
120 s, delivering a primary ion dose density (PIDD) of approxi-
mately 4.6  1012 (primary ions/cm2). Reference spectra for pure
Levoﬂoxacin and Irgasan compounds were acquired in positive and
negative ion mode from 0 to 400 Da.
2.10.2. High lateral resolution imaging
The LMIG was operated using the imaging mode, with high
lateral resolution, and Bi3
++was selected as primary ion beam. The
primary ion gun energy was 30 kV and the pulsed target current
was approximately 0.048 pA. High lateral resolution ion images
were collected over a surface area of 100 mm  100 mm, using a
pulsed analysis beam (pulse width = 100 ns). The resolution was
256  256 pixels per image (pixel width was circa 0.4 mm). Each
image was obtained with a ﬁnal ion dose of 6.5 1012 primary ions/
cm2 or less. The dose was kept below the static limit of 1013
primary ions/cm2 to minimize surface damages during the
analysis. The images were processed with the ION-TOF SurfaceLab
6.6 software (Münster, Germany).
2.10.3. 3D imaging
The LMIG and the GCIB were employed in a dual-beam
conﬁguration to collect the depth proﬁle and the 3D image data.
The LMIG was operated in pulsed mode to investigate the lateral
distribution of chemical species, while the Argon source was
operated in DC mode to remove multiple layers of material from
the sample surface between the analytical cycles. For the depth
proﬁling analysis, the dual beam experiment used a 30 kV Bi3
++
primary ion beam for analysis and a 10 kV Ar1500
+ beam for
sputtering. The pulsed current of the Bi3
++ primary ion beam was
0.048 pA and the DC current of the cluster Ar1500
+ was 10.22 nA,
with a 500 s analysis time and 4 s sputtering time. The raster areas
of the pulsed analysis beams and the DC sputter were 100 mm
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 100 mm and 300 mm  300 mm, respectively. The resolution was
256  256 pixels per image (pixel width of about 0,4 mm). Data was
collected in the negative secondary ion mode.
In the course of each acquisition, mass spectral information at
each image pixel was collected in the m/z range of 0–917 m/z.
2.11. Statistical analysis
All experiments were performed in triplicate with calculation of
means and standard deviations. Two-way analysis of variance
(ANOVA) was used for multiple comparisons along with Tukey’s
multiple comparing tests, followed by T-test to access statistical
signiﬁcance for paired comparisons. Signiﬁcance was acknowl-
edged for p values lower than 0.05.
3. Results and discussion
3.1. Rheological studies
For each polymeric solution, multiple amplitude sweeps were
used in order to correctly identify the linear viscoelastic region
(LVR). This was repeated to detect any major variations in the LVR,
and for a more accurate shear stress to be used in the frequency
sweeps. For each of the samples, elastic modulus (G’), viscous
modulus (G”) and shear viscosity (h) was calculated and
subsequently analysed.
It can be seen in Fig. 1 that for all three solutions, the viscosity
modulus (from 30 Pa to 80 Pa) is considerably greater than the
elastic modulus (0.5 Pa to 6 Pa) which implies that the solutions
exhibit signiﬁcantly less elastic properties. As observed in Fig. 1c,
both polymer-drug-loaded solutions of irgasan and levoﬂoxacin
show differences in the shear viscosity (h). The amplitude sweep
demonstrated that these drugs caused a reduction in all three of
these parameters – this may be caused by the possible transition
from semi-dilute to dilute regime, where there are less polymer
chain entanglements (Dias et al., 2013). It is also worth noting that
the LVR for the drug-loaded solutions was extended; the unloaded
PCL solution had a short LVR of between 50 Pa to 100 Pa (shear
stress), which then resulted in shear thinning at high shear
stresses. These long LVRs are indicative of well-dispersed, stable
polymer-drug systems. This behaviour of Newtonian to shear
thinning has been previously observed in other studies; it can be
attributed to the formation of physical bonding between the drug
and the polymer, which causes an increase in the solution viscosity
(Sadrearhami et al., 2015).
The frequency sweep data shown in Fig. 2 are indicative of how
the drug dispersed in the matrix affected the overall structure.
Again, it was observed that loading the polymer solution with
drugs had an effect, with measured viscosity in all three samples
appearing to be frequency dependent. According to data in both G’
and G” graphs, G” was shown to be the dominating effect
(G’ ranging from seven to 30 Pa, and G” ranging from 150 to 175 Pa).
Long regions of viscoelasticity normally imply that there is a
certain degree of stability within the polymer matrix; however, the
frequency sweep implies otherwise. It appears that G’ and G” are
both frequency dependent, which implies that the system has little
internal network and is easily disturbed (Bubel et al., 2014).
3.2. Fibre morphology
Fig. 3 shows SEM images of the various unloaded and drug-
loaded PCL scaffolds. Smooth morphology can be observed in all 3
different scaffolds and at a 12% concentration of polymer, there is
no signiﬁcant beading or any visible signs of either API outside of
the ﬁbres. The major differences across the three different scaffolds
are the ﬁbre size  the addition of irgasan reduced the average
ﬁbre diameter to 1.623 1.9 mm. These ﬁbres appear to be
relatively consistent in size compared to other various PCL-ﬁbre
studies,1.1 6.6 mm, 2.7  2.0 mm and 1.83  0.050 mm (Celebioglu
et al., 2014; Detta et al., 2010; Del Valle et al., 2011). The
Fig.1. a: Amplitude sweep viscous modulus (G’) data for PCL, PCL-IRG and PCL-LEVO solutions; b: Amplitude sweep viscous modulus (G”) data for PCL, PCL-IRG and PCL-LEVO
solutions; c: Amplitude sweep shear viscosity (h) data for PCL, PCL-IRG and PCL-LEVO solutions.
Fig. 2. a: Frequency sweep elastic modulus (G’) data for PCL, PCL-IRG and PCL-LEVO solutions; b: Frequency sweep viscous modulus (G”) data for PCL, PCL-IRG and PCL-LEVO
solutions; c: Frequency sweep shear viscosity (h) data for PCL, PCL-IRG and PCL-LEVO solutions.
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morphology of the levoﬂoxacin-loaded ﬁbres appeared to differ
from the unloaded and irgasan loaded ﬁbres: whilst there appears
to be a smooth morphology, the ﬁbres appear more densely packed
with a greater ‘curvature’ of the ﬁbres. These ﬁbres are also greater
in diameter in comparison with the PCL-IRG scaffold, with an
average ﬁbre diameter or 2.865  3.0 mm. The PCL-LEVO ﬁbres
appear to be much larger in diameter compared with studies by
Jalvandi et al. (Jalvandi et al., 2015) (600–800 nm), Puppi et al.
(Puppi et al., 2011) (219.2  55.1 nm) and Park et al. (Park et al.,
2012) (232  20.4 nm). This variation in ﬁbre diameter could
possibly be attributed to the higher voltage applied to the target
plate during the electrospinning process – for PCL and PCL-IRG
solutions, the voltage applied varied between 10 and 12 kV
whereas the PCL-LEVO solution was  18 kV. There is a critical
value of applied voltage, and the increase in the diameter with an
increase in the applied voltage are attributed to the decrease in the
size of the Taylor cone and increase in the jet velocity for the same
ﬂow rate (Haider et al., 2015).
Considering the morphology of the ﬁbres at a greater detail and
image resolution, the AFM characterisation showed a signiﬁcant
difference between the irgasan-loaded and levoﬂoxacin-loaded
ﬁbres. Fig. 4a shows the smooth morphology of the PCL-IRG
scaffold at a 400 nm scale, and it can be clearly seen that there
appears to be no signs of API on the surface of the polymer. This
suggests that the irgasan is integrated into the polymeric matrix. In
contrast, it was found using AFM that within certain areas of the
PCL-LEVO scaffold, there appeared to be regions with crystalline
API sitting at the surface (Fig. 4b).
3.3. Surface characterisation
The CAG results for the irgasan-loaded ﬁbres indicated an
increase in the hydrophobicity of the scaffold in comparison to the
unloaded PCL scaffold  the water drop took 45 min to absorb fully
into the PCL-IRG scaffold, and this slow nature of absorption
potentially indicates that the irgasan may release in a sustained
mechanism. This is most likely due to the hydrophobic nature of
irgasan combined within the polymeric matrix of PCL, which also
has a certain degree of hydrophobicity. The CAG results for the
levoﬂoxacin-loaded scaffolds were inconclusive given that hydro-
philic nature of levoﬂoxacin- the water droplet applied was
absorbed almost immediately; therefore, no data could be
obtained. However, this does support the hypothesis that there
may be an amount of levoﬂoxacin sitting at the surface of the
sample  the quick absorbance of the water droplet may be the
levoﬂoxacin uptake.
3.4. Drug efﬁcacy of electrospun scaffolds
The release of irgasan (Fig. 5) from the PCL-irgasan scaffold
appeared to exhibit sustained release behaviour of the encapsu-
lated drug. The ﬁnal cumulative drug release was found to be at
50%; although more irgasan will be released beyond 200 h
(equilibrium had not been observed at the 200 h). The behaviour
of the PCL-levoﬂoxacin scaffold was entirely different to the
irgasan-loaded scaffold. It exhibited burst release behaviour and
the antibiotic was almost entirely lost from the matrix within the
Fig. 3. SEM images of PCL (a), PCL-IRG (b) and PCL-LEVO (c) electrospun ﬁbres.
Fig. 4. a: AFM image of PCL-IRG ﬁbres; b: AFM image of PCL-LEVO ﬁbres.
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ﬁrst 15 min of measurements. The ﬁnal cumulative drug release
was also found to be at 50%. This burst release behaviour is
consistent with the manner in which the drug is associated with
the polymer matrix – the previous SEM and AFM were indicative of
the presence of levoﬂoxacin on the surface of the ﬁbres in some
areas.
Determining the drug release proﬁles of the drugs was a crucial
part of this study, as divergent behaviours helped us to characterise
bridging properties indicating the manner in which irgasan and
levoﬂoxacin dispersed within the polymer matrix. The irgasan
released steadily over 145 h, which would suggest that the drug is
being released through molecular diffusion (Yao and Weiyuan,
2010). The levoﬂoxacin exhibited a burst release mechanism,
although this may be attributed to the mechanism in which
levoﬂoxacin functions in most polymers (Park et al., 2012), due to
the way the drug is adsorbed on to the surface of the polymer
(Puppi et al., 2011; Cheow et al., 2010).
The main factors that could be expected to inﬂuence the drug
release kinetics in this study can be summarised as follows are:
 Material matrix: this includes the composition, structure and
degradation of polymer; however, the polymer showed no signs
of degradation and is known to show a high degree of stability.
 Release medium: the irgasan was released in a buffer of PBS and
sodium dodecyl sulphate (surfactant), therefore it could be
suggested either that the surfactant is interacting with the
polymer/drug or that it is changing the ionic strength of the
buffer (Thongngam and McClements, 2005).
 Drug compounds: Fu and Kao (Yao and Weiyuan, 2010) cite
solubility, stability charges and interaction with matrix as major
factors with the drug that may affect the drug release kinetics.
The results in our studies can demonstrate this, given that
potential charges of the drug were affecting fabrication,
Fig. 5. Cumulative drug release percentages for the release of IRG and LEVO in PBS
media.
Fig. 6. Images showing the average zone of inhibition of PCL-IRG and PCL-LEVO against bacterial strains of E. coli and S. aureus.
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therefore it can be assumed that the charges of irgasan and
levoﬂoxacin may be affecting the drug release kinetics.
3.5. In-Vitro antibacterial activity
The antibacterial efﬁcacy (Fig. 6) of both irgasan and
levoﬂoxacin-loaded scaffolds were tested against strains of E. coli
and S. aureus, with the efﬁcacy speciﬁcally determined by visual
zones of inhibition on the agar plate. The PCL-irgasan scaffold
showed signs of some activity, albeit weak, against E. coli with an
average inhibition zone diameter of 0.7  0.5 cm. However, the
irgasan-loaded scaffold was particularly successful inhibiting the
growth of S. aureus with an average inhibition zone diameter of
1.8  0.5 cm. There was a higher-level efﬁcacy observed within the
PCL-levoﬂoxacin cultures of both E. coli and S. aureus. Both strains
of bacteria were inhibited on the agar plate with an average
diameter of no growth of 2.6 cm. The antibacterial studies have
shown that there is a high efﬁcacy of bacteria inhibition in both
irgasan and levoﬂoxacin-loaded scaffolds across E. coli and
S. aureus bacteria. The levoﬂoxacin-loaded scaffolds demonstrated
larger values of inhibition zones, for both bacteria  this should be
the case, given that levoﬂoxacin is a broad-spectrum antibiotic,
active against both gram positive and gram negative. The irgasan-
loaded scaffold showed stronger inhibition to the S. aureus
bacteria; however, this should not be viewed as a negative result.
S. aureus is a gram-positive bacterium that is commonly found on
the skin, therefore is a major cause of nosocomial wound infection
(Sisirak et al., 2010). The hydrophobic natures of irgasan and PCL,
and potential stronger interactions between drug and polymer are
likely to aid the sustained release from the ﬁbres  this sustained
release can be observed in the previous in vitro drug release study,
and observed in the reduced inhibition of E. Coli (Celebioglu et al.,
2014).
Fig. 7. a/b: The images above are acquired with a high lateral resolution mode, which enables to easily visualise the nanoﬁbers (total ion image A and B) and the distribution of
the API (colour overlay images C and D); c: Overlay of [C6H9O2]
- (PCL) in grey and [C12H6Cl3O2]
- (Irgasan) in yellow; d: Overlay of [C6H9O2]
- (PCL) in grey and of [C17H19FN3O2]
-
and [C18H19FN3O4]
- (Levoﬂoxacin) in yellow.
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3.6. ToF-SIMS analysis
Imaging and 3D imaging techniques showed a difference in the
distribution of the active pharmaceutical ingredients (APIs)
between Irgasan-loaded and Levoﬂoxacin-loaded ﬁbres. PCL is
identiﬁed by the ion at m/z 113 ([C6H9O2]
- [M-H]-), Levoﬂoxacin by
the ions at m/z 360 ([C18H19FN3O4]
- [M-H]-) and m/z 316
([C17H19FN3O2]
-), and Irgasan by the ions at m/z 287
([C12H6
35Cl3O2]
- [M-H]-), m/z 289 ([C12H6
35Cl2
37Cl1O2]
-) and m/z
291 ([C12H6
35Cl1
37Cl2O2]
-). The total ion images and the overlays of
single ion images for the characteristic peaks of PCL (grey) and the
two drugs (yellow) are reported in Fig. 7. The ion images show a
homogeneous distribution of Irgasan, throughout the electrospun
ﬁbres, whilst the Levoﬂoxacin appears to be concentrated in
several small areas. This was conﬁrmed by 3D imaging, where
Irgasan characteristic peaks appeared to be homogeneously
distributed in the volume (Fig. 8a). Conversely, Levoﬂoxacin had
an intense signal localized to small areas and mainly on the surface
(Fig. 8b).
4. Conclusions
The purpose of this study was to fabricate drug-loaded ﬁbres
that may potentially be used within a hernia repair context. The
good understanding of the relationship between the solution
viscosity and the spinning parameters is essential if the technique
is to be effective, hence the need to characterise the effect of drug
loading on the rheological behaviour of the spinning solutions. It
was observed that the addition of both irgasan and levoﬂoxacin
had a direct inﬂuence on the rheological behaviour of the
solutions; a reduction in elastic modulus, viscous modulus, and
shear viscosity occurred, which may cause a reduction in polymer
chain entanglements. However, this explanation may not be the
only viable one  rheological behaviour of drug-loaded solutions
has been widely researched, although further characterisation into
the molecular interactions between drug and polymer may give
further insight into why the solution behaviour changes signiﬁ-
cantly. Atomic force microscopy indicated that crystals, probably of
levoﬂoxacin were present on the surface of the polymer ﬁbres, and
this was crucial in explaining the behaviour of the drug during in
vivo release studies and antibacterial activity proﬁle. The presence
of levoﬂoxacin at the surface of the polymer was conﬁrmed
through contact angle goniometry (immediate absorbance of the
water droplet showed the hydrophilic nature of levoﬂoxacin in
action), in vitro release studies (the drug demonstrated a burst
release behaviour), antibacterial studies (an increased average
inhibition zone repelled both bacteria types immediately) and ToF-
SIMS. In the ToF-SIMS study, the molecular weight of levoﬂoxacin
was shown at various areas across the ﬁbres and the 3D imaging of
the matrix indicated there was a certain degree of drug
encapsulation. This study has contrasted the incorporation of
two different drugs within an electrospun ﬁbre, and shown that
through bridging chemical, mechanical and biological studies,
their behaviours can be fully interpreted. The next stages of this
research are to now assess whether these constructs are useful
within any clinical scenario, and in particular, within the treatment
of hernia repair.
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